Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

MOGAMULIZUMAB-KPKC: 1,186 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
1,186
Total FAERS Reports
161 (13.6%)
Deaths Reported
198
Hospitalizations
1,186
As Primary/Secondary Suspect
30
Life-Threatening
10
Disabilities
Prescription
Status

FDA Application: 761051 ·

First Report: 20110501 · Latest Report: 20250904

What Are the Most Common MOGAMULIZUMAB-KPKC Side Effects?

#1 Most Reported
Rash
177 reports (14.9%)
#2 Most Reported
Disease progression
107 reports (9.0%)
#3 Most Reported
Drug eruption
62 reports (5.2%)

All MOGAMULIZUMAB-KPKC Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Rash 177 14.9% 5 15
Disease progression 107 9.0% 25 10
Drug eruption 62 5.2% 2 7
Pruritus 58 4.9% 2 7
Infusion related reaction 54 4.6% 6 6
Death 45 3.8% 45 2
Fatigue 44 3.7% 3 1
Chills 40 3.4% 0 3
Inappropriate schedule of product administration 39 3.3% 3 8
Pyrexia 39 3.3% 6 14
Drug ineffective 37 3.1% 4 2
Erythema 33 2.8% 3 6
Diarrhoea 26 2.2% 1 7
Nausea 26 2.2% 1 3
Off label use 26 2.2% 0 2
Skin disorder 25 2.1% 5 5
Condition aggravated 24 2.0% 2 7
Alopecia 23 1.9% 0 0
Lymphopenia 23 1.9% 2 4
Skin exfoliation 23 1.9% 0 2

Who Reports MOGAMULIZUMAB-KPKC Side Effects? Age & Gender Data

Gender: 17.6% female, 82.4% male. Average age: 67.9 years. Most reports from: US. View detailed demographics →

Is MOGAMULIZUMAB-KPKC Getting Safer? Reports by Year

YearReportsDeathsHosp.
2011 1 0 0
2014 8 2 2
2015 4 1 0
2016 7 3 1
2017 9 4 4
2018 41 8 9
2019 118 18 37
2020 113 13 24
2021 105 13 24
2022 65 12 24
2023 46 9 11
2024 58 6 15
2025 31 2 4

View full timeline →

What Is MOGAMULIZUMAB-KPKC Used For?

IndicationReports
Cutaneous t-cell lymphoma 589
Product used for unknown indication 283
Adult t-cell lymphoma/leukaemia 130
Cutaneous t-cell lymphoma stage iv 58
Mycosis fungoides 22
Cutaneous t-cell lymphoma stage iii 18
Cutaneous t-cell lymphoma stage ii 15
Peripheral t-cell lymphoma unspecified 11
Cutaneous t-cell lymphoma stage i 9
T-cell lymphoma 9

MOGAMULIZUMAB-KPKC vs Alternatives: Which Is Safer?

MOGAMULIZUMAB-KPKC vs MOLNUPIRAVIR MOGAMULIZUMAB-KPKC vs MOLSIDOMINE MOGAMULIZUMAB-KPKC vs MOMELOTINIB MOGAMULIZUMAB-KPKC vs MOMETASONE MOGAMULIZUMAB-KPKC vs MOMETASONE FUROATE MOGAMULIZUMAB-KPKC vs MOMETASONE FUROATE\OLOPATADINE MOGAMULIZUMAB-KPKC vs MONOMETHYL MOGAMULIZUMAB-KPKC vs MONTELUKAST MOGAMULIZUMAB-KPKC vs MONTELUKAST\MONTELUKAST MOGAMULIZUMAB-KPKC vs MONTMORILLONITE

Official FDA Label for MOGAMULIZUMAB-KPKC

Official prescribing information from the FDA-approved drug label.